Prof. Dr. Guus Rimmelzwaan
Projects of the Group
14
results.
Rift Valley Fever Vaccine development (LARISSA 2)
Rift Valley Impfstoffentwicklung (LARISSA 2)
Project Investigators: Albert Osterhaus ; Guus Rimmelzwaan
Duration: July 2023 until January 2027
VIPER 2- Immunity against CNS infections caused by the Rift Valley fever virus (RVFV)
VIPER 2- Immunität gegen ZNS-Infektionen durch das Rifttalfieber-Virus (RVFV)
Project Investigators: Prof. Dr. Albert Osterhaus; Prof. Dr. Guus Rimmelzwaan
Duration: April 2022 until March 2025
Evaluation of Rationally Designed Influenza Vaccines
Bewertung von rational konzipierten Influenza-Impfstoffen (ENDFLU)
Project Investigators: Prof. Guus Rimmelzwaan; Prof. Albert Osterhaus
Duration: August 2020 until July 2025
Improved Vaccination strategies for Older Adults
Verbesserte Impfstrategien für ältere Erwachsene (ISOLDA)
Project Investigators: Prof. Guus Rimmelzwaan; Prof. Albert Osterhaus; Husni Elbahesh, PhD
Duration: January 2020 until December 2024
Development and testing of preventive and therapeutic measures against SARS-CoV-2 using experimental animal models (COVID MWK)
Enwicklung und Testung präventiver und therapeutischer Maßnahmen gegen SARS-CoV-2 am experimentellen Tiermodell (COVID MWK)
Project Investigators: Prof. Dr. Maren von Köckritz-Blickwede; Prof. Dr. Guus Rimmelzwaan; Prof. Dr. Albert Osterhaus
Duration: June 2020 until December 2023
Does an Influenza-A-virus triggered immune response release growth factors for bacterial co-infections?
Induziert eine Influenza-A-Virus getriggerte Immunantwort Wachstumsfaktoren für bakterielle Ko-Infektionen?
Project Investigators: PD Nicole de Buhr, PhD; Simon Lassnig; Prof.in Dr. Isabel Hennig-Pauka; Prof. Dr. Guus Rimmelzwaan; Prof.in Dr. Maren von Köckritz-Blickwede
Duration: Mid 2020 until Mid 2023
10FT21 COFONI Fast-Treck - Validation of FDA-approved small molecule kinase inhibitor (SMKI) candidates as SARS-CoV-2 therapeutics in a human ex vivo system.
10FT21 COFONI Fast-Treck - Validierung von der FDA zugelassenen Kandidaten für kleinmolekulare Kinase-Inhibitoren (SMKI) als SARS-CoV-2-Therapeutika in einem menschlichen Ex-vivo-System.
Project Investigators: Prof. Guus Rimmelzwaan; Husni Elbahesh, PhD
Duration: September 2021 until August 2022
Development and testing of preventive and therapeutic measures against SARS-CoV-2 on experimental animal model ferrets, rabbits, hamsters and on the primate model
Entwicklung und Testung präventiver und therapeutischer Maßnahmen gegen SARS-CoV-2 am experimentellen Tiermodell Frettchen, Kaninchen, Hamster und am Primatenmodell
Project Investigators: Prof. Dr. Maren von Köckritz-Blickwede; Prof. Dr. Ab Osterhaus; Prof. Dr. Guus Rimmelzwaan; Prof. Dr. Wolfgang Baumgärtner; Prof. Dr. Stefan Pöhlmann
Duration: May 2020 until May 2022
Rift Valley Fever Vaccine development
Rift Valley Fever Impfstoffentwicklung (LARISSA)
Project Investigators: Prof. Guus Rimmelzwaan; Prof. Albert Osterhaus
Duration: July 2019 until December 2022
Understanding and overcoming immuno-senescence in elderly individuals
Verständnis und Überwindung der Immunseneszenz bei älteren Menschen (RESIST)
Project Investigators: Prof. Guus Rimmelzwaan; Prof. Albert Osterhaus
Duration: April 2019 until December 2022